Sentences with phrase «on clinical outcome in»

This calls for a further urgent clarification of its impact on clinical outcome in humans.

The TOPCAT trial is the first randomized, double - blind trial to assess the effect of spironolactone on clinical outcomes in these patients with heart failure and preserved ejection fraction.

In three new studies in the current issue of the International Journal of Infectious Disease, researchers reported on clinical outcomes in the Kingdom of Saudi Arabia (KSA), how long patients will shed virus during their infections, and how the Sultanate of Oman is dealing with cases that have appeared there.

RELAX - AHF was a randomised, double blind controlled trial that evaluated the effects of a 48 - hour infusion of the intravenous drug, serelaxin, on clinical outcomes in 1 161 patients admitted to hospital for acute heart failure.

«TOPCAT is the first randomized, double - blind trial to assess the effect of a treatment - spironolactone - on clinical outcomes in this patient demographic.»

The researchers designed the study, called Effect of Remote Ischemic Preconditioning on Clinical Outcomes in Coronary Artery Bypass Grafting Surgery (ERICCA), in an effort to find new ways to improve bypass outcomes for high - risk patients.

Lin, L. C., Que, J., Lin, K. L., Leung, H. W., Lu, C. L., and Chang, C. H. Effects of zinc supplementation on clinical outcomes in patients receiving radiotherapy for head and neck cancers: a double - blinded randomized study.

Not exact matches

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

This stage represents the final effect of the event on the clinician, who may leave the clinical profession altogether, stay in her previous role but never function at her previous performance level, or thrive by taking lessons learned and working to ensure that deficits in the process led to the outcome are addressed in effort to decrease the likelihood that such an event will occur.

The workshop featured presentations from invited speakers and discussions to highlight research findings that advance our understanding of the effects of maternal care services in different types of institutional settings on maternal labor, clinical and other birth procedures, and birth outcomes.

Moreover, robust evidence on the cost effectiveness of birth in alternative settings is a priority, as was highlighted by the recent National Institute for Health and Clinical Excellence (NICE) clinical guidance on intrapartum care.11 The Birthplace in England research programme was designed to fill gaps in research evidence about the processes and outcomes associated with different settings for birth in the NHS in Clinical Excellence (NICE) clinical guidance on intrapartum care.11 The Birthplace in England research programme was designed to fill gaps in research evidence about the processes and outcomes associated with different settings for birth in the NHS in clinical guidance on intrapartum care.11 The Birthplace in England research programme was designed to fill gaps in research evidence about the processes and outcomes associated with different settings for birth in the NHS in England.

The definition of low risk used in the cohort study was based on criteria contained in the NICE Intrapartum Care Guidelines.11 The primary clinical outcome was a composite measure of adverse perinatal outcomes encompassing perinatal mortality and specified neonatal morbidities (box).

Low family income during the early childhood has been linked to comparatively less secure attachment, 4 higher levels of negative moods and inattention, 5 as well as lower levels of prosocial behaviour in children.2 The link between low family income and young children's problem behaviour has been replicated across several datasets with different outcome measures, including parental reports of externalizing and internalizing behaviours,1 - 3, 7 -9,11-12 teacher reports of preschool behavioural problems, 10 and assessments of children based on clinical diagnostic interviews.7

Because the trial found no differences in the effect of type of care on any primary clinical outcome, the economic analysis compares only the costs of care rather than their cost - effectiveness.

The risk status of a pregnancy was defined using a mixture of maternal International Classification of Disease (ICD) codes [19] and individual fields in the SMMIS database, and was based on a 2007 clinical guideline from the National Institute for Health and Clinical Excellence (NICE) which contained lists of medical and obstetric conditions which indicate increased risk of negative pregnancy outcomclinical guideline from the National Institute for Health and Clinical Excellence (NICE) which contained lists of medical and obstetric conditions which indicate increased risk of negative pregnancy outcomClinical Excellence (NICE) which contained lists of medical and obstetric conditions which indicate increased risk of negative pregnancy outcomes [20].

Ms. McBride received her law degree from George Washington University Law School and her Master's Degree in Evaluative Clinical Sciences (a program focused on health policy considerations of clinical outcomes) from Dartmouth Clinical Sciences (a program focused on health policy considerations of clinical outcomes) from Dartmouth clinical outcomes) from Dartmouth College.

The Effect of Timing of Cord Clamping on Neonatal Venous Hematocrit Values and Clinical Outcome at Term: A Randomized, Controlled Trial José M. Ceriani Cernadas, Guillermo Carroli, Liliana Pellegrini, Lucas Otaño, Marina Ferreira, Carolina Ricci, Ofelia Casas, Daniel Giordano and Jaime Lardizábal Pediatrics 2006; 117; 779 - 786; originally published online Mar 27, 2006; DOI: 10.1542 / peds.2005 - 1156 Download file in 380 kb - 10 pages The online version of this article, along with updated information and services, is located on the World Wide Web at: http://www.pediatrics.org/cgi/content/full/117/4/e779 Background: The umbilical cord is usually clamped immediately after birth.

«We are currently working with people from across the field of cancer to develop a new Cancer Reform Strategy, which will set out the plans for cancer services in England over the next five to ten years, building on progress so far by spreading best practice and recommending what more needs to be done to improve clinical outcomes, drive up quality and increase value for money.»

Let me point to 10 things that I sketched out this morning: too much money spent on administration and bureaucracy and not enough on front - line patient care; too little patient - centric information to inform decision making; too little innovation; too little clinical input into decision making; too much inertia and hostility to reform, as we have seen today; too much process - driven target culture distorting clinical decision making; falling productivity; poor outcomes across a range of clinical indicators; too often, weak commissioning of servicing; and widening health inequalities in the past 10 years, in addition to the scandals that occurred in Staffordshire and Kent.

In health, information on the prescribing data and comparative clinical outcomes of GP practices will be published from December this year.

When subsequent studies found that CellSearch results had no influence on clinical outcomes, though, insurers lost interest in paying for it.

«This gives us an underlying candidate biomarker panel that provides information on the subsequent clinical outcome or therapeutic efficacy, which can be validated to yield a final panel, then translated into say, an ELISA - based kit or some other immunodiagnostic format in the clinical setting,» says Dorfman.

They now must await the outcome of the next candidate in the pipeline of more than 30 products in clinical testing and mine the STEP data for clues on ways to develop one that works.

«While the presence of lymphocytes in tumors is often associated with better clinical outcomes, this research adds clarity on the diversity of T cells within the tumor environment and their influence on ovarian cancer outcomes,» says first author Kunle Odunsi, MD, PhD, FRCOG, FACOG, Deputy Director, M. Steven Piver Professor and Chair of Gynecologic Oncology, and Executive Director of the Center for Immunotherapy at Roswell Park.

In 22 percent of cases, the additional clinical information found in the EHR was rated as «possibly» having a clinically significant impact on the interpretation of the head CT. «This study exemplifies the power of EHR's and their potential impact on patient care and positive outcomeIn 22 percent of cases, the additional clinical information found in the EHR was rated as «possibly» having a clinically significant impact on the interpretation of the head CT. «This study exemplifies the power of EHR's and their potential impact on patient care and positive outcomein the EHR was rated as «possibly» having a clinically significant impact on the interpretation of the head CT. «This study exemplifies the power of EHR's and their potential impact on patient care and positive outcomes.

Besides working at IBM's Thomas J. Watson Research Center in Yorktown Heights, New York, Meyer heads something called the DREAM challenges, contests that ask teams of computer scientists to solve outstanding biomedical problems, such as predicting the outcome of prostate cancer treatment based on clinical variables or detecting breast cancer from mammogram data.

An investigation into how patient outcomes are assessed in clinical trials has revealed a worrying lack of consistency, raising concerns about funding being wasted on the acquisition of poor quality data.

The study, Developing an Interventional Stroke Service: Improving Clinical Outcomes and Reducing Cost and Delivering Great Cost Savings Benefits to Health Economy, conducted at the University Hospital of North Midlands, Stoke - on - Trent, U.K., found that mechanical thrombectomy (the use of a device to retrieve a clot from the vessel) in the treatment of stroke reduced the average stroke patient's hospital stay to 14 days when compared to previously recorded 90 days.

The UB researchers are conducting a longitudinal, five - year study of these patients focused on the relationship between cerebral microbleeds, advances in magnetic resonance imaging and clinical outcomes.

«Using an algorithm based on genetic testing to guide treatment is sustainable and associated with better clinical outcomes in a real - world clinical practice, although it is difficult to consistently maintain,» said Craig R. Lee, Pharm.D., Ph.D., F.A.H.A., associate professor of pharmacy at the University of North Carolina at Chapel Hill Eshelman School of Pharmacy.

Since L - arginine can be given to women as a simple, safe, and inexpensive food supplement, (in peanuts, for example) in pregnancy, Dr. Kain and Dr. McDonald are now planning human clinical trials to assess its impact on human birth outcomes.

In a new study, a hospital surveillance program focusing on reducing the risks of sepsis, known as the two - stage Clinical Decision Support (CDS) system, was found to reduce the risk of adverse outcomes, such as death and hospice discharge for sepsis patients, by 30 % over the course of one year.

However, in analyses that accounted for important patient characteristics such as age, sex, comorbidities, and the reason for hospitalization, the quality of care of the discharging hospital and SNF facility characteristics, outcomes did not vary meaningfully across SNFs that differed in staffing ratings or their performance on clinical measures related to pain or delirium.

Yang et al. report on one such strategy: Taking the knowledge that an increase in type I interferons (IFNs) correlates positively with clinical outcome in several cancers and that type I IFNs can enhance antitumor immunity in some models, the authors tethered IFN - β to a monoclonal antibody targeting the epithelial growth factor receptor (EGFR), which is approved for use in treating metastatic colorectal cancer and head and neck cancer.

«The recent niacin clinical trials offer important new evidence that raising «good» cholesterol (HDL) levels on top of statin therapy does not have the positive outcome that had been hoped for,» said Neil Stone, M.D., the Robert Bonow MD Professor in Cardiology at Feinberg and a cardiologist at Northwestern Memorial Hospital.

«This is the first national study to identify specific regions of the United States where residents may be at an increased risk for poor clinical outcomes — including misdiagnoses and late detection — as a result of limited access to specialized gynecologic cancer care,» says David Shalowitz, MD, a fellow in the division of Gynecologic Oncology at the Perelman School of Medicine at the University of Pennsylvania, and lead author on the study.

The study is investigator led and has therefore focused on clinical need, targeting patients with progressive multiple sclerosis in whom most disability is incurred... The study also reports a predominant effect on neurodegenerative rather than inflammatory outcomes, suggesting a novel mechanism of action that might be suitable as combination treatment with immunomodulatory treatments... Further phase 3 studies to measure the effect of simvastatin on sustained disability, particularly in patients with non-relapsing secondary progressive and primary progressive multiple sclerosis, are clearly needed, but this trial represents a promising point from which to develop trials of progressive disease.»

However, the authors stress that «further clinical investigations will be essential to establish the optimal dose, duration and safety, and whether vitamin D2 or D3 have different effects on mortality risk, since the available trials are based on elderly populations in general (an age group with high competing risk of death often due to multiple co-existing disease conditions) and they do not typically include cause - specific deaths as the primary outcomes.»

On the other hand patients with DRB1 * 04:01 have a better clinical outcome in the short - and long - term suggesting that human leukocyte antigen (HLA) analysis and screening for SLA / LP antibodies should be integrated in the clinical routine for AIH diagnosis.

Since blood samples are taken and frozen with many clinical trials, this allows them «almost a bit of a time machine» to go back and explore questions around pain or neuropathy to run tests on neurons created from blood samples of patients taken in past clinical trials where responses and outcomes have already been recorded.»

«Additional research is needed to determine how these recommendations might be implemented in clinical practice and to understand the impact on patient outcomes.»

«Given the continued high prevalence of multivitamin use in the US, it remains critical for us to understand its role on nutritional status and other long - term health outcomes through clinical trials such as PHS II and other new research initiatives.»

Up until now, efforts in generating a vaccine against TB have been mainly focused on T cells (cells from the adaptive arm of our immune response with memory capacity), with very disappointing outcomes in both pre-clinical as well as clinical trials.

The study wasn't designed to measure whether tumor profiling made a difference in how patients fared, but «it nonetheless lays the groundwork for more systematic study of the impact of genomics on clinical practice and patient outcomes,» the report said.

«But although it has been shown to help reduce injury to the heart during surgery and in other medical contexts, unfortunately it showed no benefit on long - term clinical outcomes in our study of patients undergoing cardiac bypass surgery.»

«Many clinical trials in pulmonary hypertension also use the catheter test as an outcome measure, but it could provide a significant advantage to be able to replace it with a less invasive MRI scan, as our model also provides more detailed information on physical changes to the heart itself.»

The research, one of a number of studies to explore the connection between heart disease and development of depression by researchers at Intermountain Medical Center Heart Institute, will be published on July 28 in the European Heart Journal — Quality of Care & Clinical Outcomes.

«Diabetes raises the risk about twofold for Alzheimer's disease,» says senior author, Gail Musen, Ph.D., Assistant Investigator in the Section on Clinical, Behavioral, and Outcomes Research at Joslin Diabetes Center.

Gail Musen, Ph.D., is an Assistant Investigator in the Section on Clinical, Behavioral, and Outcomes Research and an Assistant Professor in Psychiatry at Harvard Medical School.

The effect of hepatic impairment on outcomes in phase 1 clinical trials in cancer subjects.